We all know that certain types of cancer can be inherited. What does that really mean? If you inherit a gene that predisposes you to cancer, does it guarantee that you will develop the disease?

Fortunately, the answer is no. Whether or not any particular gene causes disease, cancer in particular, depends on many other inherited traits. A recent study in mice showed that the consequences of inheriting a cancer‑causing gene depend heavily on additional genetic factors. These other inherited traits help determine whether you will get cancer at all, what kind of cancer you might develop, and, if you do, when in life it is likely to appear. This phenomenon is called epistasis. One gene's effect can be altered by other genes.

Replaying Cancer Evolution

Human cancer studies are difficult to compare because each person is unique, with a different genome, diet, environment and history of exposures. The study removed that noise by rerunning the earliest steps of cancer hundreds of times in four groups of mice. The genetic distance between the four groups matches the range observed across the human population and, in one case, exceeds it.

Every animal received a single dose of the same liver carcinogen at 15 days of age and lived under the same conditions. The study then analyzed the complete DNA sequences and gene activity of 581 liver tumors. If chemical exposure and random chance determined the outcome on their own, all four groups should have produced much the same tumors. They did not.

Tumors appeared 25 weeks after exposure in the most susceptible group and 78 weeks after exposure in the most resistant group. Untreated animals developed spontaneous liver tumors in the same order of susceptibility. The most resistant animals often developed no tumor at all under conditions that produced tumors in every animal of the most susceptible group.

Same Pathway, Different Results

Nearly all the tumors, 95% of them, carried an activating mutation in a single signaling system, the MAPK pathway . The pathway tells a liver cell when to grow and when to specialize. The DNA surrounding these mutation sites was identical across the groups, extending at least 13 letters in either direction. Therefore, a local sequence cannot explain the split.

The number of changes required to start a tumor also shifted with background. The most susceptible group typically required a single driver mutation, whereas the other groups required at least two. In the most resistant group, more than a third of tumors doubled their entire genome during the first cell division after the DNA damage. Same exposure, same target organ, same pathway. Different cancers, at different times. Sometimes no cancer at all.

What This Means for Genetic Testing

The finding speaks directly to how clinics predict risk. A report stating that a person carries a "pathogenic variant" in a cancer gene delivers one line of a much longer script. The variant matters. The rest of the genome, along with the rest of the family, matters as well.

Numbers from the clinic already hint at this. More than 60% of women who inherit a harmful change in BRCA1 or BRCA2 develop breast cancer during their lifetime, compared with about 13% of women in the general population. This leaves a large share of carriers who never develop the disease. Two people with the same BRCA1 variant can face different lifetime risks depending on the rest of their inherited genome.

Polygenic risk scores, which weigh many genes at once, already sharpen those estimates. The recent study supplies the mechanism behind them. The same driver mutation, when introduced into different genetic backgrounds, elicited different responses in the circuits that govern whether a cell keeps dividing, specializes, becomes inflamed or dies. The mutation was the same. The consequence was not.

Cancer-causing mutations and the genes you inherit do not simply add up their effects. They influence each other. Carrying a variant does not mean a person will develop the disease. The probability depends on the rest of the genome. Two people with the same result on the same test are not looking at the same risk.

Toward Personal Cancer Risk

These findings in mice reflect what we see in humans. Not everyone who inherits a cancer‑predisposing gene actually develops cancer. And just as in the mice, in those who do, the timing and type of cancer are strongly influenced by many other genetic and possibly environmental factors.

This work is part of a much broader story about how genes exert their effects. Very few genes are fully dominant in the sense that they will express the same way regardless of the broader genetic background. It is far more common for people to inherit a predisposition—a risk that may range from only a few percent to more than 50 or 60 percent—rather than a certainty. Understanding these interactions among genes helps explain why inheriting a “cancer gene” is not destiny, but rather one important element in a much more complex picture.